Is there a role for adjuvant docetaxel in patients with high-risk localized prostate cancer who elect for prostatectomy?
The role of adjuvant docetaxel with ADT following RT for high risk disease has been previously elucidated by RTOG 0521. Following prostatectomy, however, the SPCG12 abstract presented at ASCO 2016 seemed to indicate that docetaxel provided no benefit, though these patients did not recieve ADT. In your practice, are there patients to whom you offer adjuvant chemo (with or without androgen suppression) following prostatectomy?
Answer from: Medical Oncologist at Academic Institution
Currently, there is no data to support the use of adjuvant docetaxel following radical prostatectomy. Given that these are two entirely different treatments in different patient populations, there is no rationale for extrapolating the results from RTOG0521 to a post-surgical (even if high-risk) popu...
Sign in or Register to read more